INTRODUCTION AND OBJECTIVES: Multiparametric magnetic resonance imaging (mpMRI) has been shown to improve the sensitivity for detecting higher grade prostate cancer (PCa) in men with an elevated PSA. We sought to assess if the adoption of mpMRI has improved the identification of occult higher grade PCa among men enrolled in active surveillance (AS).
METHODS: We retrospectively identified men from the Johns Hopkins AS registry enrolled since 2013 (year of mpMRI adoption in our cohort) diagnosed with grade group (GG) 1 PCa and underwent a single mpMRI. Men in this group were dichotomized by the presence (n[207) or absence (negative mpMRI, n[225) of !1 PI-RADS 3-5 lesion. Both groups were compared to a third cohort of men with GG1 PCa enrolled in AS prior to 2013 (pre-mpMRI era, n[669), for risk of upgrading to GG! 2 PCa on follow-up biopsies performed with or without MRI targeting.
RESULTS: Men with mpMRI underwent a median of 2 (IQR 2-3) surveillance biopsies separated by a median interval of 13 months . These men underwent a mpMRI at a median of 11 months (IQR 9-15) following enrollment in AS (11 had mpMRI prior to diagnosis). No significant difference was observed in the frequency and interval of biopsies for men with and without a PI-RADS 3-5 lesion. Men in the pre-mpMRI era underwent a median of 3 (IQR 2-5) surveillance biopsies, with a median interval between biopsies of 12 months . On Kaplan-Meir analysis, the risk of PCa upgrading was significantly different between the three groups: the 2 and 4-year upgrade-free rates were 93% and 83%, 74% and 59%; and, 87% and 76% for the negative mpMRI, PI-RADS 3-5, and pre-mpMRI groups, respectively, (p < 0.001) [Figure] . Upon adjusting for age, PSA density, and NCCN very-low-risk/low-risk status at diagnosis, both mpMRI groups had significantly different risk of upgrading compared to pre-mpMRI group ( CONCLUSIONS: mpMRI significantly improves the risk stratification of men in AS with GG 1 PCa and should be used at the time of enrollment into AS. Men with a negative mpMRI have a relatively low risk for upgrading. Future work aims to identify the safe minimal frequency of prostate biopsies in this group with the intent of reducing biopsy related morbidity while maintaining a window of curability.
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PD50-05 VISIBLE DISEASE AT BASELINE ACCELERATES TIME TO EXIT FROM MRI-BASED ACTIVE SURVEILLANCE
Vasilis Stavrinides*, Francesco Giganti, Clement Orczyk, Shonit Punwani, Clare Allen, Alex Kirkham, Alex Freeman, Hayley Whitaker, Mark Emberton, Caroline M Moore, London, United Kingdom INTRODUCTION AND OBJECTIVES: In MRI-based active surveillance (AS) for prostate cancer, the prognostic significance of visible disease at baseline is poorly defined. We present clinical outcomes from the UCLH MRI-based AS cohort (to our knowledge, the largest in the world) and investigate the association of baseline imaging with time to AS exit.
METHODS: Follow up and clinical-histological outcomes were collected for 647 men in the UCLH AS database enrolled between August 2004 and December 2017 (Gleason 3þ3 or low-volume 3þ4 disease, PSA<20 ng/mL and baseline mpMRI; mean age: 61.8 yrs; median PSA: 6.4 ng/mL). Starting time was defined as the date of the first MRI and all men included had at least 6 months of follow up. AS exit was defined as any treatment, transition to watchful waiting (WW) and/or pathological progression to Gleason 4þ3 or higher on secondary biopsies. The Kaplan-Meier method and log rank test were used to compare time to AS exit in men with a baseline Likert score of 1-3 (no lesion) versus those with Likert 4-5 (lesion).
RESULTS: Median follow up was 53 months . In total, 172 men were treated (44 radical prostatectomy, 83 focal, 12 hormones, 17 radiotherapy [12 combined with hormones], 3 brachytherapy). Fourteen patients transitioned to WW. Pathological progression on secondary biopsy was observed in 37 men in total; 15 progressed to 4þ3 and received treatment, apart from 1 lost to follow up and 2 who transitioned to WW. Also, one patient was treated due to anxiety, 21 were lost to follow up and 36 were discharged for PSA monitoring in the community with specified PSA thresholds for rereferral. Five deaths were recorded, but only one was prostate cancer-related. There was a significant difference in time to AS exit between patients with a lesion and those without, which persisted regardless of Gleason grade at diagnosis (log rank test; p[0.0066 for Gleason 3þ3, p[0.00069 for Gleason 3þ4).
CONCLUSIONS: Men on AS with a Likert of 4-5 at baseline appear to have a significantly different clinical trajectory compared to those without a well-defined MRI lesion, regardless of cancer grade at
